A Phase 2 interventional study of Revefenacin Inhalation Solution [Yupelri] and Ipratropium Bromide in COPD and Acute Respiratory Failure, sponsored by University of California, Los Angeles. Completed at 2 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by University of California, Los Angeles · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. revefenacin · Pulmonary Disease, Chronic Obstructive.
Among the 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive, this one is the 15th largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 2, and was the 12th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive are open now, in 1 country. Recruiting first, the newest first:
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
University of Tennessee Graduate School of Medicine · Sites in United States
Ages 40+
By country, each count listing its studies:
revefenacin: first FDA approval 2018 (YUPELRI). What it is approved for, and how studies give it, is on its page →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 122 across the 17 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 17 have an industry lead sponsor. The 6 most frequent:
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
University of California, Los Angeles has 5 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
1 of the studies testing revefenacin in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07133880University of Tennessee Graduate School of MedicineCompare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive, from their registry updates:
This tab as a report to print or save as PDF → With an account.
RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.
Objective: To assess the efficacy of nebulized revefenacin in improving the lung mechanics of COPD patients with acute respiratory failure requiring invasive mechanical ventilation (MV), in comparison to a control group receiving the short-acting muscarinic antagonist ipratropium.
Hypothesis: Revefenacin is as efficacious as ipratropium in improving the lung mechanics of COPD patients with acute respiratory failure.
Study Design:
RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Revefenacin will be delivered once daily via nebulizer. In order to allow for full blinding and steady Q6 hours regimen in control arm, at hours 6, 12 and 18 after the Revefenacin dose, nebulized normal saline will be delivered.
Drug: Revefenacin Inhalation Solution [Yupelri]
Nebulized ipratropium will be delivered via nebulizer Q6 hours.
Drug: Ipratropium Bromide
nebulized drug comparison
nebulized drug comparison
Respiratory Therapist Time Spent at the Bedside (Minutes Per Day)
Respiratory therapist time spent delivering either Revefenacin or Ipratropium at the bedside (minutes per day)
Time frame: 7 days
Safety of Revefenacin: Paradoxical Bronchospasm, Hypersensitivity Reaction, Severe Urinary Retention Not Explained by Other Reasons, Severe Constipation Not Explained by Other Reasons
Number of participants who experienced adverse events not explained by other reasons
Time frame: 7 days
Reduction in Total Inspiratory Resistance Rdyn at the Time of Drug Trough
Time frame: From the peak to trough within 24 hours
Ventilator Days to Day 28
Time spent on ventilator from the day of enrollment in the study through Day 28
Time frame: 28 days post enrollment
Survival to Day 28
alive at Day 28
Time frame: 28 days
| Milestone | Revefenacin | Ipratropium |
|---|---|---|
| Started | 12 | 9 |
| Completed | 12 | 9 |
| Not completed | 0 | 0 |
Respiratory therapist time spent delivering either Revefenacin or Ipratropium at the bedside (minutes per day)
| minutes per day | Revefenacin Arm | Ipratropium Arm |
|---|---|---|
| Respiratory Therapist Time Spent at the Bedside (Minutes Per Day) | 7.2 ± 1.0 | 26.8 ± 5.3 |
Number of participants who experienced adverse events not explained by other reasons
| events | Revefenacin | Ipratropium |
|---|---|---|
| Paradoxical bronchospasms | 0 | 0 |
| Hypersensitivity reaction | 0 | 0 |
| New Cardiac arrhythmia | 0 | 1 |
| Severe urinary retention | 1 | 0 |
| Severe constipation | 0 | 0 |
| cmH2O/L/s | Revefenacin | Ipratropium |
|---|---|---|
| Reduction in Total Inspiratory Resistance Rdyn at the Time of Drug Trough | -0.9 ± 2.4 | 2.6 ± 3.3 |
Time spent on ventilator from the day of enrollment in the study through Day 28
| day | Revefenacin | Ipratropium |
|---|---|---|
| Ventilator Days to Day 28 | 11.2 ± 10.5 | 12.2 ± 9.8 |
alive at Day 28
| Participants | Revefenacin | Ipratropium |
|---|---|---|
| Survival to Day 28 | 12 | 5 |
Collected over Hospital stay length, up to 60 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Revefenacin | 2/12 (16.7%) | 0/12 (0%) | 2/12 (16.7%) |
| Ipratropium | 4/9 (44.4%) | 0/9 (0%) | 1/9 (11.1%) |
| Event | Revefenacin | Ipratropium |
|---|---|---|
| arrhythmiaCardiac disorders | 0/12 | 1/9 |
| Urinary retentionRenal and urinary disorders | 1/12 | 0/9 |
| transaminitisHepatobiliary disorders | 1/12 | 0/9 |
| Age, Categorical(Participants) | Revefenacin | Ipratropium | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 1 | 1 |
| >=65 years | 12 | 8 | 20 |
| Age, Continuous(years) | Revefenacin | Ipratropium | Total |
|---|---|---|---|
| Mean | 77 ± 7 | 75 ± 16 | 76 ± 11 |
| Sex: Female, Male(Participants) | Revefenacin | Ipratropium | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 6 | 5 | 11 |
| Race (NIH/OMB)(Participants) | Revefenacin | Ipratropium | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 2 |
| Black or African American | 2 | 4 | 6 |
| White | 9 | 3 | 12 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(participants) | Revefenacin | Ipratropium | Total |
|---|---|---|---|
| United States | 12 | 9 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2020 to primary completion in Jan 2025, 50 months.
Results were first posted in Oct 2026, 1 year 9 months after primary completion.
Of 47 non-industry phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's 50 months is above that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Revefenacin
Pulmonary Disease, Chronic Obstructive →
University of California, Los Angeles →